Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 683-688

  Griniatsos, John ^a   Diamantis, Eleftherios ^b   Gioti, Julia ^a   Karyda, Irene ^a   Vassilopoulos, Pericles P ^a   Agnanti, Niki ^c  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Breast cancer; Prognostic factors; Prostate specific antigen (PSA)

Indexed keywords

MUTANT PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RECURRENCE; CYTOSOL; FEMALE; FLUOROMETRY; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUOROMETRY; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031943382     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wernert N, Albrech M, Sesterhenn I, Goebbels R, Bonkhoff H, Seitz G, Inniger R, Remberger K: The «Female Prostate»; location, morphology, immunohistochemical characteristics and significance. Eur Urol 22: 64-69, 1992.
2. Yu H, Diamandis EP: Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 39: 2108-2114, 1993.
3. Yu H, Diamandis EP, Sutherland DJ: Immunoreactive prostatespecific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75-79, 1994.
4. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P: Prostate specific antigen is a new favorable prognostic indication for women with breast cancer. Cancer Res 55 (2): 2104-2109, 1995.
5. Diamandis EP, Yu H, Sutherland DJA: Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 301-310, 1994.
6. Yu H, Diamandis EP, Zarghami N, Gross L: Induction of prostatespecific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 32: 291-300, 1994.
7. Monne M, Croce CM, Yu H, Diamandis EP: Molecular characterization of prostate-specific antigen mRNA expressed in breast tumors. Cancer Res 54: 6344-6347, 1994.
8. Illustrated guide to the TNM/p TNM classification of malignant tumors. In: B. Spiess, O.H., Beahrs, P. Hermanek, R.V. P. Hutter, O. Scheibe, L.H. Sobin, G. Wagner (eds), TNM Atlas, Ed 3 Berlin: Springer-Verlag, 1989.
9. Bloom HJG, Richardson WN: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
10. Thorphe SM, Rose C, Rasmussen BB, King WJ, DeSombre ER, Blough RM, Mouridsen HT, Rossing R, Anderson KW: Steroid hormone receptors as prognostic indicators in primary breast cancer. Breast Cancer Res Treat 7 (Suppl): 91-98, 1986.
11. Thorphe SM: Steroid receptors in breast cancer: sources of interlaboratory variation in dextran-charcoal assays. Breast Cancer Res Treat 9: 175-189, 1987.
12. Hassapoglidou S, Diamantis EP, Sutherland DJA: Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 8: 1501-1509, 1993.
13. Fisher B, Bauer M, Wickermann DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer, an NSABP update. Cancer (Phila)52: 1551-1557, 1983.
14. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992.
15. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206-1219, 1993.
16. Porter-Jordan K, Lippman M-E: Overview of the biologic markers of breast cancer. Hematol Oncol Clin N Am 8: 73-100, 1994.
17. Lea OA, Kyinnsland S, Thorsen T: Improved measurement of androgen receptors in human breast cancer. Cancer Res 49: 7167-67, 1989.
18. Kuenen-Boumeester V, Van-Der-Kwast TH, Van-Putten WLJ, Claassen C, Van-Doijen B, Henzen-Logmans SC: Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer 52: 581-584, 1992.
19. De Lunoit V, Dauvois S, Dufour M, Simard J, Labrie F: Inhibition of cell cycle kinetics and proliferation by the androgen 5a-dihydrotestosterone and antiestrogen A', nbutyl-N-methyl-11-[16'a-chloro-3', 17b-dihydroxy-estra-2',3'5' - [10' Hriene-7a-yi] undecanamide in human breast cancer 2R-75-1 cells. Cancer Res 51: 2797-2802, 1991.
20. Dauvois S, Geng, SC, Levespue C, Merand Y, Labrie F: Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human 2R-75-1 breast tumors in athymic mice. Cancer Res 51: 3131-3135, 1991.